The S&P 500 added 0.9% on Monday, June 16, as investors absorbed the possibility of cooling geopolitical tensions and looked ...

F or the past 60 years, a committee of independent experts has advised the federal government on vaccine policy, providing ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

REGINA, SASKATCHEWAN / ACCESS Newswire / June 16, 2025 / Consumer Choice Award (CCA) is proud to announce that Affordable ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

Planning Underway for Expedited Follow-up RC and Diamond Programs HIGHLIGHTS 2,882m reverse circulation (RC) drilling ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

NEW YORK CITY, NEW YORK / ACCESS Newswire / June 14, 2025 / New to The Street (NTTS) and High Performance Battery Technology ...

The drugmaker plans to ask for FDA approval of the vaccine this year, while other pharmaceutical companies are also working on RSV vaccines. CNBC: Moderna: RSV Vaccine Effective In Preventing Disease ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report). The company’s shares closed yesterday at $27.35. Co ...

Piper Sandler analyst Edward Tenthoff maintained a Buy rating on Moderna (MRNA – Research Report) today and set a price target of $69.00. The company’s shares closed yesterday ...

Public health and infectious disease experts said they were surprised and confused about the move, and questioned why the HHS ...